165 related articles for article (PubMed ID: 24764582)
1. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
[TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.
Németh A; Bányai GL; Dobos NK; Kós T; Gaál A; Varga Z; Buzás EI; Khamari D; Dank M; Takács I; Szász AM; Garay T
Cell Commun Signal; 2024 May; 22(1):282. PubMed ID: 38778340
[TBL] [Abstract][Full Text] [Related]
3. BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.
Doxie DB; Greenplate AR; Gandelman JS; Diggins KE; Roe CE; Dahlman KB; Sosman JA; Kelley MC; Irish JM
Pigment Cell Melanoma Res; 2018 Nov; 31(6):708-719. PubMed ID: 29778085
[TBL] [Abstract][Full Text] [Related]
4. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Schilling B; Sondermann W; Zhao F; Griewank KG; Livingstone E; Sucker A; Zelba H; Weide B; Trefzer U; Wilhelm T; Loquai C; Berking C; Hassel J; Kähler KC; Utikal J; Al Ghazal P; Gutzmer R; Goldinger SM; Zimmer L; Paschen A; Hillen U; Schadendorf D;
Ann Oncol; 2014 Mar; 25(3):747-753. PubMed ID: 24504444
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Lai X; Friedman A
BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
[TBL] [Abstract][Full Text] [Related]
7. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract][Full Text] [Related]
8. Near complete remission of an inoperable pancreatic acinar cell carcinoma after BRAF-/MEK-inhibitor treatment-A case report and review of the literature.
von Fritsch L; von Bubnoff N; Weber K; Kirfel J; Schreiber C; Keck T; Wellner U
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23222. PubMed ID: 38340027
[TBL] [Abstract][Full Text] [Related]
9. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1.
Hu R; Hou H; Li Y; Zhang M; Li X; Chen Y; Guo Y; Sun H; Zhao S; Liao M; Cao D; Yan Q; Chen X; Yin M
Theranostics; 2024; 14(2):593-607. PubMed ID: 38169595
[No Abstract] [Full Text] [Related]
10. Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.
De Carli A; Kapelyukh Y; Kursawe J; Chaplain MAJ; Wolf CR; Hamis S
NPJ Syst Biol Appl; 2024 May; 10(1):51. PubMed ID: 38750040
[TBL] [Abstract][Full Text] [Related]
11. An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell-Based Cancer Vaccine.
Guo J; Muse E; Christians AJ; Swanson SJ; Davila E
Cancer Immunol Res; 2019 Sep; 7(9):1523-1534. PubMed ID: 31266784
[TBL] [Abstract][Full Text] [Related]
12. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
Meraz-Torres F; Niessner H; Plöger S; Riel S; Schörg B; Casadei N; Kneilling M; Schaller M; Flatz L; Macek B; Eigentler T; Rieß O; Garbe C; Amaral T; Sinnberg T
J Exp Clin Cancer Res; 2024 Jan; 43(1):30. PubMed ID: 38263136
[TBL] [Abstract][Full Text] [Related]
13. Exceptional Response of
Kerle IA; Scheuble AM; Kobitzsch B; Stocker G; Hiller GGR; Badendick M; William D; Krueger A; Gross T; Koegler A; Hartig A; Richter D; Aust DE; Schroeck E; Heining C; Glimm H; Hacker UT
JCO Precis Oncol; 2024 May; 8():e2400030. PubMed ID: 38820503
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract][Full Text] [Related]
15. The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation.
Wiemer AJ; Wernimont SA; Cung TD; Bennin DA; Beggs HE; Huttenlocher A
Biochem Pharmacol; 2013 Sep; 86(6):770-81. PubMed ID: 23928188
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Balancing immune responses - multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma.
Pape K; Protopapa M; Schraad M; Steffen F; Zipp F; Bittner S
Front Oncol; 2023; 13():1303141. PubMed ID: 38074649
[TBL] [Abstract][Full Text] [Related]
17. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.
Dennison L; Mohan AA; Yarchoan M
Curr Oncol Rep; 2021 Feb; 23(2):23. PubMed ID: 33547983
[TBL] [Abstract][Full Text] [Related]
18. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
Sidaway P
Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
[No Abstract] [Full Text] [Related]
19. Dabrafenib Promotes Schwann Cell Differentiation by Inhibition of the MEK-ERK Pathway.
Park K; Shin Y; Lee G; Park H; Choi Y
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917810
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma.
Yuan L; Mishra R; Patel H; Abdulsalam S; Greis KD; Kadekaro AL; Merino EJ; Garrett JT
J Cancer; 2018; 9(24):4665-4676. PubMed ID: 30588251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
